Regulatory T Cells (Tregs) in SLE: Biology and Use in Treatment. We review how Tregs dysfunction in SLE has been manipulated experimentally and preclinically in the attempt to restore, at last in part, the immune disturbances in the disease. PubMed, Curr Rheumatol Rep, 2016 Nov;18(11):67. (Also see B Cells and T Cells)
The incidence and risk of osteoporosis in patients with anxiety disorder (AD): A Population–based retrospective cohort study. The risk ratios are the highest for osteoporosis within 1 year of AD diagnosis, but the risk remains statistically significant for »1 year and clinicians should pay particular attention to osteoporotic comorbidities in AD patients. PubMed, Medicine (Baltimore), 2016 Sep;95(38):e4912. (Also see Osteoporosis and Anxiety and Attitude)
Serum level of neopterin is not a marker of disease activity in treated rheumatoid arthritis patients. The results indicated that neopterin is a marker of RA but not a marker of disease activity in treated RA patients. PubMed, Clin Rheumatol, 10/03/2016. (Also see Diagnosis of Rheumatoid Arthritis)
Disease Activity, Glucocorticoid (GC) Exposure, and Rituximab Determine Body Composition Changes during Induction Treatment of ANCA–Associated Vasculitis (AAV). Findings suggest that changes in BMI are independently associated with improvements in disease activity as well as GC exposure in AAV and rituximab may also have effects on BMI independent of its impact on disease activity. PubMed, Arthritis Care Res (Hoboken), 10/01/2016. (Also see Vasculitis and Biologic Agents)
Defining low disease activity (LDA) in systemic lupus erythematosus (SLE). LDA and remission groups had similar short term outcomes and both had better outcomes and prognosis than the high disease activity group. Wiley Online Library, Arthritis Care and Research, 10/01/2016. (Also see What is Systemic Lupus Erythematosus (SLE)?)
Stillbirth: the impact of antiphospholipid syndrome (aPL)? Emerging evidence suggests that treatment with heparin agents and low dose aspirin to prevent fetal death is imperfect and new therapeutic approaches for patients with lupus anticoagulant or triple aPL positivity are needed. PubMed, Lupus, 10/03/2016. (Also see Antiphospholipid Syndrome)
Disseminated cytomegalovirus (CMV) infection complicating active treatment of systemic lupus erythematosus: an emerging problem. Given the rise in prevalence of CMV, there is a need for appropriate screening for this opportunistic pathogen and studies to determine the risks and benefits of prophylactic or preemptive treatment for this virus. PubMed, Lupus, 10/04/2016. (Also see Symptoms and Complications of Lupus)
Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease. Our results suggest that ILD remains an important and significant source of mortality in patients with inflammatory myopathies and as such should be screened for and treated aggressively. PubMed, Lung, 2016 Oct;194(5):733-7. (Also see Myopathy and Myositis)
The effect of etanercept on traditional metabolic risk factors for cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA). Patients with RA are at an increased risk of CVD and treatment with etanercept did not adversely affect levels of metabolic risk factors for CVD in patients with RA. PubMed, Clin Rheumatol, 10/05/2016. (Also see Treatments for Rheumatoid Arthritis and Biologic Agents)
A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate (HA/CS) versus dimethyl sulfoxide (DMSO) in women with bladder pain syndrome/interstitial cystitis. Treatment with HA/CS appears to be as effective as DMSO with a potentially more favorable safety profile and both treatments increased health-related quality of life. PubMed, Neurourol Urodyn, 09/21/2016. (Also see Interstitial Cystitis)
United Way of Central New Mexico
United Way of Snohomish County
See ISN News for recent donors, including Juliet Youkhana; and donations in loving memory of Jim Miller and Arlene Marie Petulla.
Click Here to Donate or Shop
or click on the floating green DONATE sclero.org button.
SCLERO.ORG is the world leader for trustworthy research, support, education and awareness for scleroderma and related illnesses, such as pulmonary hypertension. We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: